9, RUE DE BITBOURG, LUXEMBOURG, N4
Receives FDA Approval for New SIMLANDI® Manufacturing Process That More Than Doubles Output Per Batch
Announce first known regulatory submission worldwide for proposed biosimilar to Eylea® 8 mg
Announce US-based manufacturing agreement to increase global supply
FDA approves additional U.S. manufacturing capacity for SIMLANDI®, biosimilar to Humira®
Announces FDA Acceptance for Review of Biologics License Application for AVT80, Expanding Proposed Biosimilar Program for Entyvio® to Subcutaneous Presentations
Announces Licensing and Commercialization Agreement for Proposed Biosimilars to Durvalumab and Emicizumab in the U.S. and Selected Asian Markets
Announces Financial Results for the First Half of 2026 and Provides a Business Update
Material disclosure
Annual and Transition Report of Foreign Private Issuers
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis
RW
No filings found
Amended Schedule 13D - Ownership Report
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report
Free Writing Prospectus
Submission Upload
Correspondence
Automatic Shelf Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis